Fig. 1

WEE2-AS1 expression in different types of tumors, including glioma

(A) and (B) The expression levels of WEE2-AS1 in 33 tumor tissues (A) and glioma tissues (B) from RNA-Seq data in The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases (Wilcoxon rank sum test, p < 0.001) (ACC, adrenal cortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, Cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, lymphoid neoplasm diffuse large b-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma). (C) Quantitative real-time polymerase chain reaction (RT-qPCR) analysis was used to detect WEE2-AS1 expression in three glioma cell lines (T98, U251, and A172) and a normal human astrocyte (NHA) cell line (unpaired t-test, p < 0.0001). (D) WEE2-AS1 expression in 10 glioma tissues and 6 normal brain tissues was determined using RT-qPCR (unpaired t-test, p < 0.0001). Data are represented as median ± upper and lower interquartile range. ns, no significance; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001